Fatty Liver in the CaReMeLO Patient – New Perspectives

Did you know that many primary care physicians are likely to meet patients with undiagnosed MASLD long before any symptoms develop?

Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognised as a key part of the cardiometabolic continuum, closely linked to obesity, type 2 diabetes, cardiovascular disease and chronic kidney disease. As obesity and diabetes continue to rise worldwide, primary care physicians are increasingly likely to see patients with undiagnosed MASLD long before any liver-related symptoms appear.

Yet MASLD often goes unrecognised in primary care. Many clinicians report uncertainty about who to assess, how to evaluate fibrosis risk, when to refer and how to coordinate care with other specialties. At the same time, new evidence is emerging and the treatment landscape is changing, which makes early identification more important than ever.

In this live webinar, an international faculty will share practical guidance on identifying, assessing and managing MASLD within the broader context of cardiometabolic disease. The session reflects educational priorities set by the CaReMeLO Scientific Committee and learner feedback, and it focuses on what you can apply in routine practice, from non-invasive fibrosis assessment to multidisciplinary management.